Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke with The Hill for an article on drug companies and where they stand on raising or lowering their prices.
The publication noted that the Trump administration has pressured drug companies to limit increases, and four companies—Novartis, Roche, Bayer and Merck KGaA—have announced they will not raise their prices this year, while U.S.-based Merck will lower its prices on select medicines.
“It’s clearly a time when there’s a lot of scrutiny on drug companies and pricing decisions. It makes sense that each company is thinking about the potential public relations and political implications of price increases,” said Spatz.
Read the article here.